Impact of dose and volume on subcutaneous fibrosis
De Santis, M.; Luzi, S.; Errico, A.; Frascino, V.; Mangiacotti, M.G.; Picardi, V.; Morganti, A.G.
Rays 30(2): 169-173
2005
ISSN/ISBN: 0390-7740 PMID: 16294910 Document Number: 586255
The multifactorial genesis of radiation-induced fibrosis makes a general outline of the occurence of this late toxicity fairly unpredictable. Scientific knowledge about dose fractionation, irradiated volume, total time, conformation procedures including IMRT can help provide better treatments. Chemical and physical therapies aimed at the removal of fibrosis are still limited or under study. The system of monitoring late toxicity used by the authors is presented.
Document emailed within 1 workday
Related Documents
Nardone, L.; Palazzoni, G.; D'Angelo, E.; Deodato, F.; Gambacorta, M.A.; Miccichè, F.; Morganti, A.G. 2005: Impact of dose and volume on lymphedema Rays 30(2): 149-155Shinozaki, M.; Kawara, S.; Hayashi, N.; Kakinuma, T.; Igarashi, A.; Takehara, K. 1997: Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor beta--simultaneous application with basic fibroblast growth factor causes persistent fibrosis Biochemical and Biophysical Research Communications 240(2): 292-297
Blugerman, G.; Schavelzon, D.; Dreszman, R. 2003: Intralesional use of 5-FU in subcutaneous fibrosis Journal of Drugs in Dermatology: Jdd 2(2): 169-171
Sato, M.; Miyamori, T.; Koyanagi, J.; Murase, J.; Saka, S.; Ishii, N.; Nishi, T.; Yamagishi, T. 2012: 2 cases of successful symptom management at home by using opioid rotation from a fentanyl preparation to a continuous subcutaneous injection of morphine hydrochloride, at a dose less than the equivalent dose based on the conversion table Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(Suppl 1): 58-60
Lissoni, P.; Brivio, F.; Brivio, O.; Fumagalli, L.; Gramazio, F.; Rossi, M.; Emanuelli, G.; Alderi, G.; Lavorato, F. 1995: Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients Journal of Biological Regulators and Homeostatic Agents 9(1): 31-33
Lamas, A.; Máiz, L.; Ruiz de Valbuena, M.; González-Casbas, Jé.Manuel.; Suárez, L. 2014: Subcutaneous implant with etonogestrel (Implanon®) for catamenial exacerbations in a patient with cystic fibrosis: a case report Bmc Pulmonary Medicine 14: 165
Rimal, J.; Shrestha, A. 2015: Validation of Nepalese Oral Health Impact Profile14 and Assessment of its Impact in Patients with Oral Submucous Fibrosis in Nepal Journal of Nepal Health Research Council 13(29): 43-49
Shelton, J.D.; Halpern, V. 2014: Subcutaneous DMPA: a better lower dose approach Contraception 89(5): 341-343
Sticklin, L.A.; Dubbelde, K.; Larson, E. 1989: Nursing care of the patient receiving subcutaneous low-dose Ara-C therapy Oncology Nursing Forum 16(3): 365-369
Rau, R. 2005: Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with RA Journal of Rheumatology 32(7): 1412; Author Reply 1412-3
Lowe, G.D.; Morrice, J.J.; Fulton, A.; Forbes, C.D.; Prentice, C.R.; Barbenel, J.C. 1978: Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study Thrombosis and Haemostasis 40(1): 134-143
de Braud, F.; Biganzoli, L.; Bajetta, E.; Colleoni, M.; Zampino, M.G. 1993: Subcutaneous low-dose interleukin-2 plus alpha interferon in advanced malignant melanoma Tumori 79(3): 187-190
Holmann, J.C.; Schibler, A.; Kraemer, R. 1989: Characteristics of inspiratory flow-volume curves in children with bronchial asthma and patients with cystic fibrosis Schweizerische Medizinische Wochenschrift 119(48): 1713-1718
Zhou, Y.; Yang, L.; Shi, J. 2015: Successful treatment of one case after acute paraquat intoxication complicated with pulmonary fibrosis, mediastinal emphysema and subcutaneous emphysema Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 33(9): 702-703
Popov, I.; Jelić, S.; Kovcin, V. 1995: A pilot study of low dose alpha-2b interferon in metastatic malignant melanoma with predominant subcutaneous metastases Srpski Arhiv Za Celokupno Lekarstvo 123(1-2): 5-7
Sorkhi, H.; Dooki, M.Reza.Esmaeli.; Ebrahimnejad, M.Sadat. 2006: Low-dose intradermal and subcutaneous versus intramuscular hepatitis B vaccination in primary non-responding hemodialysis patients Journal of the Medical Association of Thailand 89(10): 1648-1653
Matsuda, H. 1989: Determination of the optimal dose of crystalloid cardioplegia using volume per myocardial weight Journal of Thoracic and Cardiovascular Surgery 98(5 Part 1): 800
Belzunegui, J.; Intxausti, J.J.; De Dios, J.R.; López-Domínguez, L.; Queiro, R.; González, C.; Figueroa, M. 2001: Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate Clinical and Experimental Rheumatology 19(6): 727-730
Burgers, J.M. 1978: Tongue implants: discussion of some dose-time-volume parameters and afterloading techniques Radiologia Clinica 47(3): 204-214
Roth, J.; Hünig, R.; Hügli, C. 1995: Dose-volume histograms for optimization of radiotherapy planning based on the example of esophageal carcinoma Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 171(3): 149-153